300601 康泰生物
已收盘 06-29 15:00:00
资讯
新帖
简况
6月29日康泰生物涨5.56%，疫苗ETF嘉实基金重仓该股
证券之星 · 06-29 16:51
6月29日康泰生物涨5.56%，疫苗ETF嘉实基金重仓该股
康泰生物涨5.56%，东海证券二个月前给出“买入”评级
证券之星 · 06-29 16:51
康泰生物涨5.56%，东海证券二个月前给出“买入”评级
每周股票复盘：康泰生物（300601）不修正转股价格
证券之星 · 06-21
每周股票复盘：康泰生物（300601）不修正转股价格
康泰生物（300601）披露公司及全资子公司提供担保进展公告，6月17日股价下跌0.52%
证券之星 · 06-17
康泰生物（300601）披露公司及全资子公司提供担保进展公告，6月17日股价下跌0.52%
康泰生物（300601）披露不向下修正“康泰转2”转股价格的公告，6月16日股价上涨0.35%
证券之星 · 06-16
康泰生物（300601）披露不向下修正“康泰转2”转股价格的公告，6月16日股价上涨0.35%
6月15日康泰生物现355.09万元大宗交易
证券之星 · 06-15
6月15日康泰生物现355.09万元大宗交易
康泰生物(300601.SZ)拟零元受让北京琨远51%股权 拓宽公司业务发展空间
智通财经 · 06-15
康泰生物(300601.SZ)拟零元受让北京琨远51%股权 拓宽公司业务发展空间
康泰生物（300601）披露控股股东部分股份质押公告，5月21日股价下跌2.75%
证券之星 · 05-21
康泰生物（300601）披露控股股东部分股份质押公告，5月21日股价下跌2.75%
康泰生物涨7.16%，东海证券一周前给出“买入”评级
证券之星 · 05-11
康泰生物涨7.16%，东海证券一周前给出“买入”评级
康泰生物：以未分配利润向全体股东每10股派0.35元（含税）现金红利
证券之星 · 04-22
康泰生物：以未分配利润向全体股东每10股派0.35元（含税）现金红利
4月22日康泰生物涨5.99%，疫苗ETF嘉实基金重仓该股
证券之星 · 04-22
4月22日康泰生物涨5.99%，疫苗ETF嘉实基金重仓该股
康泰生物：公司有布局创新治疗产品，目前尚处在前期阶段
证券之星 · 04-21
康泰生物：公司有布局创新治疗产品，目前尚处在前期阶段
康泰生物最新公告：一季度净利润同比增长48.61%
证券之星 · 04-21
康泰生物最新公告：一季度净利润同比增长48.61%
康泰生物：公司没有九价HPV项目的研发
证券之星 · 04-21
康泰生物：公司没有九价HPV项目的研发
康泰生物最新公告：二价肠道病毒灭活疫苗开启Ⅰ期临床试验
证券之星 · 04-17
康泰生物最新公告：二价肠道病毒灭活疫苗开启Ⅰ期临床试验
康泰生物最新公告：吸附无细胞百白破联合疫苗获临床试验批准
证券之星 · 04-08
康泰生物最新公告：吸附无细胞百白破联合疫苗获临床试验批准
康泰生物（300601）披露2026年第一季度可转换公司债券转股情况公告，4月3日股价下跌2.95%
证券之星 · 04-03
康泰生物（300601）披露2026年第一季度可转换公司债券转股情况公告，4月3日股价下跌2.95%
康泰生物最新公告：全资子公司吸附破伤风疫苗获药品注册证书
证券之星 · 04-03
康泰生物最新公告：全资子公司吸附破伤风疫苗获药品注册证书
康泰生物（300601）披露持股5%以上股东一致行动人内部股份转让完成公告，3月26日股价下跌1.1%
证券之星 · 03-26
康泰生物（300601）披露持股5%以上股东一致行动人内部股份转让完成公告，3月26日股价下跌1.1%
3月24日康泰生物现7765.74万元大宗交易
证券之星 · 03-24
3月24日康泰生物现7765.74万元大宗交易
加载更多
公司概况
公司名称：
深圳康泰生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2017-02-07
主营业务：
深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。
发行价格：
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":11.58,"timestamp":1782716628000,"preClose":10.97,"halted":0,"volume":23388599,"delay":0,"changeRate":0.0556,"floatShares":900000000,"shares":1117000000,"eps":0.0728,"marketStatus":"已收盘","change":0.61,"latestTime":"06-29 15:00:00","open":10.91,"high":11.88,"low":10.7,"amount":267000000,"amplitude":0.1076,"askPrice":11.59,"askSize":21,"bidPrice":11.58,"bidSize":181,"shortable":0,"etf":0,"ttmEps":0.0728,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782783000000},"marketStatusCode":5,"adr":0,"adjPreClose":10.97,"symbolType":"stock","openAndCloseTimeList":[[1782696600000,1782703800000],[1782709200000,1782716400000]],"highLimit":12.07,"lowLimit":9.87,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116930261,"isCdr":false,"pbRate":1.34,"roa":"--","peRate":159.065934,"roe":"0.35%","epsLYR":0.06,"committee":0.69338,"marketValue":12934000000,"turnoverRate":0.026,"status":0,"floatMarketCap":10426000000},"requestUrl":"/m/hq/s/300601/","defaultTab":"news","newsList":[{"id":"2647322147","title":"6月29日康泰生物涨5.56%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322147?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:51","pubTimestamp":1782723114,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日康泰生物涨5.56%创60日新低，收盘报11.58元，换手率2.6%，成交量23.39万手，成交额2.67亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元，最新净值0.5806，较上一交易日下跌4.27%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","562860","BK0046","BK0239","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647732291","title":"康泰生物涨5.56%，东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647732291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647732291?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:51","pubTimestamp":1782723104,"startTime":"0","endTime":"0","summary":"今日康泰生物涨5.56%，收盘报11.58元。2026年4月28日，东海证券研究员杜永宏,付婷发布了对康泰生物的研报《公司简评报告：收入端平稳，产品管线布局丰富》，该研报对康泰生物给出“买入”评级。公司持续推进创新研发，新产品陆续获批上市，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国投证券的冯俊曦、李奔。康泰生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645233096","title":"每周股票复盘：康泰生物（300601）不修正转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2645233096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645233096?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:27","pubTimestamp":1781983630,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，康泰生物报收于11.52元，较上周的11.75元下跌1.96%。本周，康泰生物6月18日盘中最高价报11.77元。本次交易不涉及现金对价支付，由康泰生物承担后续出资义务。自2026年5月26日至2026年6月15日，康泰生物股票在连续三十个交易日中已有十五个交易日的收盘价低于当期转股价格的85%，触发“康泰转2”转股价格向下修正条款。公司于2026年6月15日召开董事会审议通过不向下修正转股价格的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300601","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644742640","title":"康泰生物（300601）披露公司及全资子公司提供担保进展公告，6月17日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644742640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644742640?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:42","pubTimestamp":1781707338,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，康泰生物报收于11.54元，较前一交易日下跌0.52%，最新总市值为128.89亿元。近日，康泰生物发布《关于公司及全资子公司提供担保进展的公告》。公告显示，深圳康泰生物制品股份有限公司及全资子公司北京民海生物科技有限公司于2026年4月21日经董事会审议通过，互为对方金融机构融资提供连带责任保证担保。截至公告日，公司及子公司对外担保本金合计5,716.62万元，占2025年度经审计净资产的0.59%，无逾期担保及其他对外担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643753875","title":"康泰生物（300601）披露不向下修正“康泰转2”转股价格的公告，6月16日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643753875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643753875?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:44","pubTimestamp":1781603055,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，康泰生物报收于11.6元，较前一交易日上涨0.35%，最新总市值为129.56亿元。公告显示，自2026年5月26日至2026年6月15日，公司股票在连续三十个交易日中已有十五个交易日的收盘价低于当期转股价格的85%，触发“康泰转2”转股价格向下修正条款。公司于2026年6月15日召开第八届董事会第十次会议，审议通过不向下修正“康泰转2”转股价格的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600032017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643743712","title":"6月15日康泰生物现355.09万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2643743712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643743712?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:41","pubTimestamp":1781516467,"startTime":"0","endTime":"0","summary":"证券之星消息，6月15日康泰生物发生大宗交易，交易数据如下：大宗交易成交价格11.75元，相对当日收盘价溢价1.64%，成交30.22万股，成交金额355.09万元，买方营业部为机构专用，卖方营业部为机构专用。近三个月该股共发生18笔大宗交易，合计成交13.39万手，溢价成交18笔。截至2026年6月15日收盘，康泰生物报收于11.56元，下跌1.62%，换手率1.7%，成交量15.28万手，成交额1.77亿元。本文数据来源于深圳证券交易所大宗交易信息披露，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500022467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643271761","title":"康泰生物(300601.SZ)拟零元受让北京琨远51%股权 拓宽公司业务发展空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2643271761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643271761?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:28","pubTimestamp":1781515732,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)发布公告，公司拟以零元受让北京琨远生物科技有限公司(简称“北京琨远”)原股东持有的已认缴但尚未实缴的51%股权(对应认缴注册资本5100万元，实缴注册资本0元)，且实现并表。鉴于标的公司于2026年3月6日注册成立，存续时间较短，且交易对手方所转让股权对应的注册资本尚未实缴，各方协商确定此次交易作价零元。此次收购旨在拓宽公司业务发展空间，实现业务多元化发展，增强公司的持续经营能力，强化公司的核心竞争优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康泰生物(300601.SZ)拟零元受让北京琨远51%股权 拓宽公司业务发展空间","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300601","BK0239","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637057381","title":"康泰生物（300601）披露控股股东部分股份质押公告，5月21日股价下跌2.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637057381","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637057381?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:49","pubTimestamp":1779356986,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，康泰生物报收于13.44元，较前一交易日下跌2.75%，最新总市值为150.12亿元。该股当日开盘13.8元，最高14.0元，最低13.4元，成交额达1.75亿元，换手率为1.41%。公司于近日披露《关于控股股东、实际控制人部分股份质押的公告》。质押起始日为2026年5月19日，到期日为2027年5月18日。截至公告日，杜伟民累计质押股份78,650,000股，占其所持股份比例27.62%，占公司总股本比例7.04%。公司表示其质押股份不存在平仓风险，不会导致实际控制权变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100033381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","BK0046","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409450","title":"康泰生物涨7.16%，东海证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409450?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:37","pubTimestamp":1778488663,"startTime":"0","endTime":"0","summary":"今日康泰生物涨7.16%，收盘报15.57元。2026年4月28日，东海证券研究员杜永宏,付婷发布了对康泰生物的研报《公司简评报告：收入端平稳，产品管线布局丰富》，该研报对康泰生物给出“买入”评级。公司持续推进创新研发，新产品陆续获批上市，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为10.47%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国投证券的冯俊曦、李奔。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629041656","title":"康泰生物：以未分配利润向全体股东每10股派0.35元（含税）现金红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2629041656","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629041656?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:52","pubTimestamp":1776862329,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：康泰生物2025年的业绩公告哪天发布？康泰生物回复：您好，公司2025年具体业绩情况及2026年经营计划详见公司于2026年4月21日在巨潮资讯网披露的2025年年度报告相关内容。暂以2026年3月31日公司总股本1,116,929,755股计算，合计拟派发现金分红金额为39,092,541.43元（含税），占2025年度归属于上市公司股东的净利润比例为55.58%，本次分红方案尚需股东会审议批准后方可实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200051458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300601","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629001543","title":"4月22日康泰生物涨5.99%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629001543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629001543?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:33","pubTimestamp":1776846839,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日康泰生物涨5.99%，收盘报14.68元，换手率4.8%，成交量43.23万手，成交额6.44亿元。重仓康泰生物的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元，最新净值0.698，较上一交易日下跌1.04%，近一年上涨13.79%。该公募基金现任基金经理为周泉希。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["562860","BK0046","BK0201","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049080","title":"康泰生物：公司有布局创新治疗产品，目前尚处在前期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629049080?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:42","pubTimestamp":1776768137,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物04月21日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100044316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629087010","title":"康泰生物最新公告：一季度净利润同比增长48.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629087010","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629087010?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:20","pubTimestamp":1776766829,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，2026年第一季度实现营业收入6.31亿元，同比下降2.18%；归属于上市公司股东的净利润为3333.90万元，同比增长48.61%。业绩变动主要系本报告期受研发资本化时点变更影响及研发投入减少、利息收入减少、资产减值损失减少等因素综合影响所致。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100042364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629822840","title":"康泰生物：公司没有九价HPV项目的研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2629822840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629822840?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:57","pubTimestamp":1776765435,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，沃森年报显示2025年全年研发投入3亿多，贵司有多个项目在研需要研发投入，全年总研发投入3亿多九价HPV是停滞了吗？2025年公司全年研发投入6.33亿元，占当年营业收入的23.69%，具体在研产品情况详见公司于2026年4月21日在巨潮资讯网披露的2025年年度报告相关内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100040631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227051","title":"康泰生物最新公告：二价肠道病毒灭活疫苗开启Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227051","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227051?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:31","pubTimestamp":1776421882,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司全资子公司北京民海生物科技有限公司研发的二价肠道病毒灭活疫苗(Vero细胞)已完成Ⅰ期临床试验准备工作，正式开启Ⅰ期临床试验，并成功完成首例受试者入组。该疫苗适用于6月龄及以上EV-A71、CV-A16易感者，用于预防手足口病等传染病。目前全球尚无二价肠道病毒灭活疫苗（Vero细胞）获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700037526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","BK0046","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625454149","title":"康泰生物最新公告：吸附无细胞百白破联合疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625454149","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625454149?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:41","pubTimestamp":1775648460,"startTime":"0","endTime":"0","summary":"康泰生物公告称，公司全资子公司北京民海生物科技有限公司研发的吸附无细胞百白破(组分)联合疫苗于近日获得国家药品监督管理局出具的《药物临床试验批准通知书》，同意本品进行临床试验。该疫苗适用于成人、青少年及儿童，用于预防百日咳、白喉、破伤风。目前国内厂家暂无吸附无细胞百白破（组分）联合疫苗的产品获批上市。公司将尽快开展相关临床试验工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800033668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300601","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624141659","title":"康泰生物（300601）披露2026年第一季度可转换公司债券转股情况公告，4月3日股价下跌2.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624141659","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624141659?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:39","pubTimestamp":1775209157,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，康泰生物报收于13.81元，较前一交易日下跌2.95%，最新总市值为154.25亿元。该股当日开盘14.12元，最高14.22元，最低13.8元，成交额达1.32亿元，换手率为1.05%。近日，深圳康泰生物制品股份有限公司发布2026年第一季度可转换公司债券转股情况公告。2026年第一季度，共有60张“康泰转2”完成转股，合计转为380股公司股票。截至2026年3月31日，剩余可转债为19,989,850张，票面总金额为1,998,985,000元。公司总股本由1,116,929,375股增至1,116,929,755股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624943656","title":"康泰生物最新公告：全资子公司吸附破伤风疫苗获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624943656","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624943656?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:01","pubTimestamp":1775206912,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司全资子公司北京民海生物科技有限公司研发的吸附破伤风疫苗于今日收到国家药品监督管理局签发的《药品注册证书》。该疫苗主要用于发生创伤机会较多的人群及妊娠期妇女，以预防破伤风。此次获批将进一步丰富公司产品布局，增强核心竞争力。但产品上市时间存在不确定性，敬请投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300032835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300601","BK0239","159646","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622853590","title":"康泰生物（300601）披露持股5%以上股东一致行动人内部股份转让完成公告，3月26日股价下跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622853590","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622853590?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:28","pubTimestamp":1774517330,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，康泰生物报收于13.45元，较前一交易日下跌1.1%，最新总市值为150.23亿元。该股当日开盘13.61元，最高13.77元，最低13.39元，成交额达1.09亿元，换手率为0.89%。公告显示，公司于2026年3月24日完成持股5%以上股东袁莉萍及其一致行动人之间的内部股份转让计划。本次转让属于一致行动人之间内部转让，合计持股比例未发生变化，不涉及向市场减持，不影响公司治理结构和控制权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600031741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050315","title":"3月24日康泰生物现7765.74万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050315?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:01","pubTimestamp":1774342891,"startTime":"0","endTime":"0","summary":"证券之星消息，3月24日康泰生物发生大宗交易，交易数据如下：近三个月该股共发生25笔大宗交易，合计成交22.8万手，折价成交7笔，溢价成交17笔。该股近期无解禁股上市。截至2026年3月24日收盘，康泰生物(300601)报收于13.66元，上涨3.72%，换手率1.22%，成交量11.02万手，成交额1.48亿元。该股近半年内有股东持股变动，合计净减持209.34万股，股东增减持明细如下表：该股最近90天内共有1家机构给出评级，买入评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400028025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782756701856,"stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":-0.0855},{"period":"3month","weight":-0.165},{"period":"6month","weight":-0.2136},{"period":"1year","weight":-0.2324},{"period":"ytd","weight":-0.2136}],"compareEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":0.0013},{"period":"3month","weight":0.0468},{"period":"6month","weight":0.0265},{"period":"1year","weight":0.1897},{"period":"ytd","weight":0.0265}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"61919人(较上一季度增加1.07%)","perCapita":"14541股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111693万元","survey":" 深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}